Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer

Summary

This is an interventional study, to assess feasibility and safety of durvalumab (MEDI4736) in neo-adjuvant setting in patients with resectable NSCLC. Additional analyses of potential imaging biomarkers, e.g. Zr-89 labelled durvalumab (MEDI4736), ex vivo In-111-oxine labelled CD8+ T-cells and high-resolution immune cell imaging, in relation to immunotherapy induced immune responses on quantitative immune histochemical analysis of the resected tumor specimen, will be performed.

Timeline

Start

2019-09-19

Primary completion

2022-12-06

Completion

2022-12-06

Drugs

Indications